Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Barbieri

Showing results (251-260 of 305) with videos related to

Pageof 31
Sort By:
NEJM Evidence|June 20, 2022
Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black MenSpyridon P Basourakos, Roman Gulati, Randy A Vince, et al.
Acta Biomaterialia|June 15, 2018
Bone matrix development in steroid-induced osteoporosis is associated with a consistently reduced fibrillar stiffness linked to altered bone mineral qualityL Xi, P De Falco, E Barbieri, et al.
European Journal of Cancer (Oxford, England : 1990)|November 28, 2017
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry studyA Musolino, F Falcini, A Sikokis, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 24, 2017
Vasectomy and Risk of Prostate Cancer in a Screening TrialJonathan Shoag, Oleksander Savenkov, Paul J Christos, et al.
BMC Cancer|August 23, 2023
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)Ariel E Marciscano, Sydney Wolfe, Xi Kathy Zhou, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019L Moscetti, E Barbieri, E Zattarin, et al.
British Journal of Cancer|August 30, 2012
Human responses against HER-2-positive cancer cells in human immune system-engrafted miceC De Giovanni, G Nicoletti, L Landuzzi, et al.
Cell Death & Disease|August 7, 2015
NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosisY Shi, I T Ma, R H Patel, et al.
Cyberpsychology & Behavior : the Impact of the Internet, Multimedia and Virtual Reality on Behavior and Society|January 31, 2009
Virtual environments in the diagnosis, prevention, and intervention of age-related diseases: a review of VR scenarios proposed in the EC VETERAN ProjectG Riva, A Rizzo, D Alpini, et al.
European Urology Open Science|December 10, 2020
Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular SubtypesSalma Ben-Salem, Qiang Hu, Yang Liu, et al.
Pageof 31

Showing results (251-260 of 305) with videos related to

Sort By:
Pageof 31
NEJM Evidence|June 20, 2022
Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black MenSpyridon P Basourakos, Roman Gulati, Randy A Vince, et al.
Acta Biomaterialia|June 15, 2018
Bone matrix development in steroid-induced osteoporosis is associated with a consistently reduced fibrillar stiffness linked to altered bone mineral qualityL Xi, P De Falco, E Barbieri, et al.
European Journal of Cancer (Oxford, England : 1990)|November 28, 2017
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry studyA Musolino, F Falcini, A Sikokis, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 24, 2017
Vasectomy and Risk of Prostate Cancer in a Screening TrialJonathan Shoag, Oleksander Savenkov, Paul J Christos, et al.
BMC Cancer|August 23, 2023
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)Ariel E Marciscano, Sydney Wolfe, Xi Kathy Zhou, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019L Moscetti, E Barbieri, E Zattarin, et al.
British Journal of Cancer|August 30, 2012
Human responses against HER-2-positive cancer cells in human immune system-engrafted miceC De Giovanni, G Nicoletti, L Landuzzi, et al.
Cell Death & Disease|August 7, 2015
NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosisY Shi, I T Ma, R H Patel, et al.
Cyberpsychology & Behavior : the Impact of the Internet, Multimedia and Virtual Reality on Behavior and Society|January 31, 2009
Virtual environments in the diagnosis, prevention, and intervention of age-related diseases: a review of VR scenarios proposed in the EC VETERAN ProjectG Riva, A Rizzo, D Alpini, et al.
European Urology Open Science|December 10, 2020
Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular SubtypesSalma Ben-Salem, Qiang Hu, Yang Liu, et al.
Pageof 31